Ragnhild Sørum Falk (born 1980) is cand.scient. in biostatistics and took her PhD in 2013 on the thesis Epidemiological studies of early-stage breast cancer in the Norwegian breast cancer screening program. She works at the Oslo Centre for Biostatistics and Epidemiology at Oslo University Hospital.
The author has completed the ICMJE form and declares no conflicts of interest.
Hofvind S, Geller B, Vacek PM et al. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007; 22: 447 – 55. [PubMed] [CrossRef]
2.
Day NE. Overdiagnosis and breast cancer screening. Breast Cancer Res 2005; 7: 228 – 9. [PubMed] [CrossRef]
3.
Marmot MG, Altman DG, Cameron DA et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013; 108: 2205 – 40. [PubMed] [CrossRef]
4.
Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res 2013; 15: R41. [PubMed] [CrossRef]
5.
de Gelder R, Heijnsdijk EA, van Ravesteyn NT et al. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 2011; 33: 111 – 21. [PubMed] [CrossRef]
6.
Puliti D, Duffy SW, Miccinesi G et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012; 19 (suppl 1): 42 – 56. [PubMed] [CrossRef]
Duffy SW, Smith RA. More on screening mammography. N Engl J Med 2011; 364: 283. [PubMed]
10.
Haldorsen T, Tretli S, Ursin G. Overdiagnosis of invasive breast cancer due to mammography screening. Ann Intern Med 2012; 157: 220. [PubMed] [CrossRef]
Benestad HB, Laake P. Forskning: Metode og planlegging. I: Benestad HB, Laake P, red. Forskningsmetode i medisin og biofag. Oslo: Gyldendal Akademisk, 2004: 83 – 113.
13.
Kalager M, Zelen M, Langmark F et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203 – 10. [PubMed] [CrossRef]
14.
Olsen AH, Lynge E, Njor SH et al. Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer 2013; 132: 208 – 14. [PubMed] [CrossRef]
15.
Hofvind S, Ursin G, Tretli S et al. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer 2013; 119: 3106 – 12. [PubMed] [CrossRef]
16.
Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004; 328: 921 – 4. [PubMed] [CrossRef]
Kalager M, Adami HO, Bretthauer M et al. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491 – 9. [PubMed] [CrossRef]
20.
Falk RS, Hofvind S, Skaane P et al. Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer 2013; 133: 705 – 12. [PubMed] [CrossRef]
Det er uenighet om hvor mange prosent overdiagnostikk av brystkreft det er ved mammografiscreening. Tallene varierer fra 10% til 50%. Falk hevder at forskjellene kan forklares med hvorvidt man bruker aggregerte data eller individdata og med lengde på…
If you do not see the PDF file or want to save the file, you can right-click on the PDF icon. Select «Save target / file as ...» and then retrieve the PDF file in, for example, Acrobat Reader.
RE: Hvorfor er resultater fra organisert mammografiscreening
13.09.2016Det er uenighet om hvor mange prosent overdiagnostikk av brystkreft det er ved mammografiscreening. Tallene varierer fra 10% til 50%. Falk hevder at forskjellene kan forklares med hvorvidt man bruker aggregerte data eller individdata og med lengde på…